4-(4-cyano-benzoyl)-piperazine-1-carboxylic acid tert-butyl ester | 220470-24-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 4-(4-cyano-benzoyl)-piperazine-1-carboxylic acid tert-butyl ester
• 英文别名: tert-butyl 4-(4-cyanobenzoyl)piperazine-1-carboxylate；4-(4-Cyanobenzoyl)-1-piperazinecarboxylic Acid 1,1-Dimethylethyl Ester
• CAS: 220470-24-6
• 化学式: C₁₇H₂₁N₃O₃
• mdl: MFCD17861151
• 分子量: 315.372
• InChiKey: AWCWKIIMNWGBRM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  23
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  73.6
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-(4-cyano-benzoyl)-piperazine-1-carboxylic acid tert-butyl ester 在 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 生成 1-(4-cyanobenzoyl)piperazine
  参考文献：
  名称：

  Synthesis and biological evaluation of substituted 4-(thiophen-2-ylmethyl)-2H-phthalazin-1-ones as potent PARP-1 inhibitors

  摘要：

  We have developed a series of substituted 4-(thiophen-2-ylmethyl)-2H-phthalazin-1-ones as potent PARP-1 inhibitors. Preliminary biological evaluation indicated that most compounds possessed inhibitory potencies comparable to, or higher than AZD-2281. Among these compounds, 18q appeared to be the most notable one, which displayed an 8-fold improvement in enzymatic activity compared to AZD-2281. These efforts lay the foundation for our further investigation.

  DOI：

  10.1016/j.bmcl.2014.07.001
• 作为产物：
  描述：

  对氰基苯甲酸 在 氯化亚砜 、 potassium carbonate 作用下， 以 二氯甲烷 、 乙腈 为溶剂， 反应 8.0h， 生成 4-(4-cyano-benzoyl)-piperazine-1-carboxylic acid tert-butyl ester
  参考文献：
  名称：

  一类厚朴酚衍生物及其制备方法与应用

  摘要：

  本发明公开了一类结构如式Ⅵ、Ⅴ所示的厚朴酚衍生物或其药学上可接受的盐，R选自#imgabs0#R’选自H、C1‑C4烷基。经试验表明，与厚朴酚相比，本发明所述的厚朴酚衍生物或其药学上可接受的盐的抗肝癌活性均有所提升，同时可以明显抑制肝癌细胞的迁移。本发明还公开了所述的厚朴酚衍生物或其药学上可接受的盐在制备治疗肝癌药物中的应用。#imgabs1#

  公开号：

  CN117820287A

文献信息

• [EN] 3-ARYL-5-SUBSTITUTED-ISOQUINOLIN-1-ONE COMPOUNDS AND THEIR THERAPEUTIC USE<br/>[FR] COMPOSÉS DE 3-ARYLISOQUINOL-1-ONE 5-SUBSTITUÉE ET LEUR UTILISATION THÉRAPEUTIQUE
  申请人：CANCER RES INST ROYAL

  公开号：WO2015036759A1

  公开（公告）日：2015-03-19

  The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain 3-aryl-5-substituted- 2/-/-isoquinolin-1-one compounds that, inter alia, inhibit PARP (e.g., PARP1, TNKS1, TNKS2, etc.) and/or Wnt signalling. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit PARP (e.g., PARP1, TNKS1, TNKS2, etc.); to inhibit Wnt signalling; to treat disorders that are ameliorated by the inhibition of PARP (e.g., PARP1, TNKS1, TNKS2, etc.); to treat disorders that are ameliorated by the inhibition of Wnt signalling; to treat proliferative conditions such as cancer, etc. Formula (I)

  本发明涉及治疗化合物领域。更具体地，本发明涉及某些3-芳基-5-取代-2/-/-异喹啉-1-酮化合物，该化合物在抑制PARP（例如PARP1、TNKS1、TNKS2等）和/或Wnt信号传导方面具有作用。本发明还涉及包含此类化合物的药物组合物，以及使用这些化合物和组合物在体外和体内抑制PARP（例如PARP1、TNKS1、TNKS2等）；抑制Wnt信号传导；治疗通过抑制PARP（例如PARP1、TNKS1、TNKS2等）改善的疾病；治疗通过抑制Wnt信号传导改善的疾病；治疗增生性疾病如癌症等。公式（I）
• N-benzenesulfonyl-L-proline compounds, preparation method and method for using the compounds in therapy
  申请人：Fournier Industrie et Sante

  公开号：US06384222B1

  公开（公告）日：2002-05-07

  The present invention relates to compounds selected from the group consisting of: (i) the compounds of the formula  in which X is a halogen atom, A is a group —NH—(CH2)n—NH—CO—, —NH—CH2— or Q is a group R1 is hydrogen, halogen, C1-C3 alkyl or C1-C5 1-oxoalkyl, R2 is H or OH and n is 2, 3 or 4; and (ii) their addition salts. It further relates to the process for their preparation and to their use in therapeutics, especially for combating pathological conditions involving bradykinin.

  本发明涉及从以下组合中选择的化合物：（i）式中X是卤素原子，A是一个组- NH-（CH2）n-NH-CO-，-NH-CH2-或Q是一个组R1是氢，卤素，C1-C3烷基或C1-C5 1-氧代烷基，R2是H或OH，n为2、3或4；和（ii）它们的加成盐。它进一步涉及它们的制备过程及其在治疗中的使用，特别是用于对抗涉及激肽酶的病理条件。
• [EN] CARBAMIC ACID COMPOUNDS COMPRISING A PIPERAZINE LINKAGE AS HDAC INHIBITORS<br/>[FR] COMPOSES D'ACIDE CARBAMIQUE COMPRENANT UN CHAINON DE PIPERAZINE TELS QUE LES INHIBITEURS HDAC
  申请人：PROLIFIX LTD

  公开号：WO2003082288A1

  公开（公告）日：2003-10-09

  This invention pertains to certain carbamic acid compounds which inhibit HDAC (histone deacetylase) activity of the following formula:[Insert formula]wherein: Cy is independently a cyclyl group; Q1 is independently a covalent bond or cyclyl leader group; the piperazin-1,4-diyl group is optionally substituted; J1 is independently a covalent bond or -C(=O)- ; J2 is independently -C(=O)- or -S(=O)2- ; Q2 is independently an acid leader group; wherein: Cy is independently: C3-20carbocyclyl, C3-20heterocyclyl, or C5-20aryl; and is optionally substituted; Q1 is independently: a covalent bond; C1-7alkylene; or C1-7alkylene-X-C1-7alkylene, -X-C1-7alkylene, or C1-7alkylene-X-, wherein X is -O- or -S-; and is optionally substituted; Q2 is independently: C4-8alkylene; and is optionally substituted; and has a backbone length of at least 4 atoms; or: Q2 is independently: C5-20arylene; C5-20arylene-C1-7alkylene; C1-7alkylene-C5-20arylene; or, C1-7alkylene-C5-20arylene-C1-7alkylene; and is optionally substituted; and has a backbone length of at least 4 atoms; or a pharmaceutically acceptable salt, solvate, amide, ester, ether, chemically protected form, or prodrug thereof. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit HDAC, and in the treatment of conditions mediated by HDAC, cancer, proliferative conditions, psoriasis, etc.

  本发明涉及一些碳酰胺化合物，其抑制以下式的HDAC（组蛋白去乙酰化酶）活性：[插入式]其中：Cy独立地是环烷基团；Q1独立地是共价键或环烷基团；哌嗪-1,4-二基基团可选地被取代；J1独立地是共价键或-C（=O）-；J2独立地是-C（=O）-或-S（=O）2-；Q2独立地是酸基团；其中：Cy独立地是C3-20碳环烷基、C3-20杂环烷基或C5-20芳基；并可选地被取代；Q1独立地是：共价键；C1-7烷基；或C1-7烷基-X-C1-7烷基、-X-C1-7烷基或C1-7烷基-X-，其中X是-O-或-S-；并可选地被取代；Q2独立地是：C4-8烷基；并可选地被取代；并且具有至少4个原子的骨架长度；或：Q2独立地是：C5-20芳基；C5-20芳基-C1-7烷基；C1-7烷基-C5-20芳基；或C1-7烷基-C5-20芳基-C1-7烷基；并可选地被取代；并且具有至少4个原子的骨架长度；或其药学上可接受的盐、溶剂化合物、酰胺、酯、醚、化学保护形式或前药。本发明还涉及包含这种化合物的制药组合物，以及这种化合物和组合物的使用，无论是体外还是体内，用于抑制HDAC，并用于治疗由HDAC介导的疾病，如癌症、增殖性疾病、牛皮癣等。
• Carbamic acid compounds comprising a piperazine linkage as hdac inhibitors
  申请人：Watkins J. Clare

  公开号：US20050143385A1

  公开（公告）日：2005-06-30

  This invention pertains to certain carbamic acid compounds which inhibit HDAC (histone deacetylase) activity of the following formula: wherein: Cy is independently a cyclyl group; Q 1 is independently a covalent bond or cyclyl leader group; the piperazin-1,4-diyl group is optionally substituted; J 1 is independently a covalent bond or —C(═;O)—; J 2 is independently —C(═O)— or —S(═O) 2 —; Q 2 is independently an acid leader group; wherein: Cy is independently: C 3-20 carbocyclyl, C 3-20 heterocyclyl, or C 5-20 aryl; and is optionally substituted; Q 1 is independently: a covalent bond; C 1-7 alkylene; or C 1-7 alkylene-X—C 1-7 alkylene, —X—C 1-7 alkylene, or C 1-7 alkylene-X—, wherein X is —O— or —S—; and is optionally substituted; Q 2 is independently: C 4-8 alkylene; and is optionally substituted; and has a backbone length of at least 4 atoms; or: Q 2 is independently: C 5-20 arylene; C 5-20 arylene-C 1-7 alkylene; C 1-7 alkylene-C 5-20 arylene; or, C 1-7 alkylene-C 5-20 arylene-C 1-7 alkylene; and is optionally substituted; and has a backbone length of at least 4 atoms; or a pharmaceutically acceptable salt, solvate, amide, ester, ether, chemically protected form, or prodrug thereof. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit HDAC, and in the treatment of conditions mediated by HDAC, cancer, proliferative conditions, psoriasis, etc.

  本发明涉及某些卡巴酸类化合物，其抑制以下式中的HDAC（组蛋白去乙酰化酶）活性：其中：Cy独立地是环烷基团；Q1独立地是共价键或环烷基团；哌嗪-1,4-二基基团可选择性取代；J1独立地是共价键或-C（═;O）-；J2独立地是-C（═O）-或-S（═O）2-；Q2独立地是酸性基团；其中：Cy独立地是C3-20碳环烷基、C3-20杂环烷基或C5-20芳基；并且可选择性取代；Q1独立地是：共价键；C1-7烷基；或C1-7烷基-X-C1-7烷基，-X-C1-7烷基或C1-7烷基-X-，其中X为-O-或-S-；并且可选择性取代；Q2独立地是C4-8烷基；并且可选择性取代；并且具有至少4个原子的骨架长度；或：Q2独立地是C5-20芳基、C5-20芳基-C1-7烷基、C1-7烷基-C5-20芳基或C1-7烷基-C5-20芳基-C1-7烷基；并且可选择性取代；并且具有至少4个原子的骨架长度；或其药学上可接受的盐、溶剂化合物、酰胺、酯、醚、化学保护形式或前药。本发明还涉及包含这样的化合物的制药组合物，以及这样的化合物和组合物的使用，无论是在体外还是体内，以抑制HDAC，并用于治疗由HDAC介导的疾病，如癌症、增殖性疾病、牛皮癣等。
• CARBAMIC ACID COMPOUNDS COMPRISING A PIPERAZINE LINKAGE AS HDAC INHIBITORS
  申请人：WATKINS Clare J.

  公开号：US20080269237A1

  公开（公告）日：2008-10-30

  This invention pertains to certain carbamic acid compounds which inhibit HDAC (histone deacetylase) activity of the following formula: The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit HDAC, and in the treatment of conditions mediated by HDAC, cancer, proliferative conditions, psoriasis, etc.

  本发明涉及以下化学式中抑制HDAC（组蛋白去乙酰化酶）活性的某些碳酰胺类化合物：同时，本发明还涉及包含这些化合物的药物组合物，以及这些化合物和组合物的使用，无论是在体内还是体外，以抑制HDAC，并用于治疗由HDAC介导的疾病，如癌症、增殖性疾病、银屑病等。